Means and methods for the treament of B cell non-hodgkin lymphoma and B cell leukemia
Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.
1. A method for treating or ameliorating relapse and/or recurrence of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) or relapse and/or recurrence of B cell leukemia in a subject suffering from relapsed and/or recurrent B NHL and/or B cell leukemia, the method comprising administering to the subject a pharmaceutical composition comprising a bispecific single chain antibody comprising the amino acid sequence set forth in SEQ ID NO: 2,
wherein the bispecific single chain antibody is administered in a daily dose over at least six hours by continuous intravenous infusion for at least four weeks, wherein a lower daily dose of less than 10 μg to 80 μg per square meter patient body surface area of the bispecific single chain antibody is administered as an initial dose followed by a higher maintenance daily dose.
2. The method according to claim 1 , wherein the initial dose is between 0.5-5 μg per square meter patient body surface area per 24 hours and the maintenance daily dose is 15 μg per square meter patient body surface area per 24 hours.
3. The method according to claim 1 , wherein the initial dose is 15 μg per square meter patient body surface area and the maintenance daily dose is 45 μg per square meter patient body surface area.
4. The method according to claim 2 , wherein the initial dose is 5 μg per square meter patient body surface area per 24 hours and the maintenance daily dose is further increased to 45 μg per square meter patient body surface area per 24 hours for the remaining period of the treatment.
5. The method according to claim 1 , wherein the bispecific single chain antibody is administered in a daily dose by continuous intravenous infusion for at least eight weeks.
6. The method according to claim 5 , wherein the bispecific single chain antibody is administered in a daily dose by continuous intravenous infusion for at least twelve weeks.
7. A method for treating or ameliorating relapse and/or recurrence of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) or relapse and/or recurrence of B cell leukemia in a subject suffering from relapsed and/or recurrent B NHL and/or B cell leukemia, the method comprising administering to the subject a pharmaceutical composition comprising a bispecific single chain antibody comprising the amino acid sequence set forth in SEQ ID NO: 2,
wherein the bispecific single chain antibody is administered in a daily dose over at least six hours by continuous intravenous infusion for at least four weeks, wherein a lower daily dose of 5 μg per square meter patient body surface area of the bispecific single chain antibody is administered as an initial dose followed by a higher maintenance daily dose of 15 μg per square meter patient body surface area of the bispecific single chain antibody.
8. The method according to claim 7 , wherein the bispecific single chain antibody is administered in a daily dose by continuous intravenous infusion for at least eight weeks.
9. The method according to claim 8 , wherein the bispecific single chain antibody is administered in a daily dose by continuous intravenous infusion for at least twelve weeks.
10. The method according to claim 7 , wherein the maintenance daily dose is further increased to 45 μg per square meter patient body surface area for the remaining period of the treatment, and wherein the daily dose is administered over at least 8 hours.